The patent, titled "Methods and Compositions for Oral Administrations of Proteins," covers a core concept of the company’s technology.
Oramed CEO Nadav Kidron said, "The Japanese patent approval represents a great success in further establishing the global standing of Oramed’s innovative oral delivery technology."
The patent has also been approved in Israel and Australia, according to the company.
Currently Oramed’s portfolio consists of seven issued patents and 28 pending patents.